Drugs / BZ371A
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05332340 | Nov 2022 | erectile dysfunction, prostate cancer | Biozeus Biopharmaceutical S.A. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06651541 | Jul 2026 → Jun 2027 expected | physiological sexual disorder, sexual disorder | Biozeus Biopharmaceutical S.A. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06116045 | Oct 2024 → Feb 2025 overdue | sexual disorder | Biozeus Biopharmaceutical S.A. | Recruiting | No outcome recorded |
| Phase 2 | NCT05558007 | Nov 2023 → Dec 2024 overdue | erectile dysfunction, prostate cancer | Biozeus Biopharmaceutical S.A. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BZ371A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06651541 ↗ |
| Route | Topical | “topically administered” NCT05332340 ↗ |